company background image
A042

HansBiomed KOSDAQ:A042520 Stock Report

Last Price

₩10.60k

Market Cap

₩103.5b

7D

-4.5%

1Y

-26.6%

Updated

11 May, 2022

Data

Company Financials
A042520 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health1/6
Dividends0/6

A042520 Stock Overview

HansBiomed Corporation, together with its subsidiaries, engages in the research and development, production, and sale of medical materials for the procedure and the raw materials for medical supplies.

HansBiomed Competitors

Price History & Performance

Summary of all time highs, changes and price drops for HansBiomed
Historical stock prices
Current Share Price₩10,600.00
52 Week High₩17,400.00
52 Week Low₩10,250.00
Beta0.24
1 Month Change-8.62%
3 Month Change-14.52%
1 Year Change-26.64%
3 Year Change-59.85%
5 Year Change-39.26%
Change since IPO67.99%

Recent News & Updates

Apr 10
Are Dividend Investors Making A Mistake With HansBiomed Corporation (KOSDAQ:042520)?

Are Dividend Investors Making A Mistake With HansBiomed Corporation (KOSDAQ:042520)?

Is HansBiomed Corporation ( KOSDAQ:042520 ) a good dividend stock? How can we tell? Dividend paying companies with...

Mar 06
Does HansBiomed (KOSDAQ:042520) Have A Healthy Balance Sheet?

Does HansBiomed (KOSDAQ:042520) Have A Healthy Balance Sheet?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Jan 30
HansBiomed's(KOSDAQ:042520) Share Price Is Down 63% Over The Past Three Years.

HansBiomed's(KOSDAQ:042520) Share Price Is Down 63% Over The Past Three Years.

The truth is that if you invest for long enough, you're going to end up with some losing stocks. But the long term...

Shareholder Returns

A042520KR BiotechsKR Market
7D-4.5%-4.1%-3.3%
1Y-26.6%-34.3%-14.3%

Return vs Industry: A042520 exceeded the KR Biotechs industry which returned -36% over the past year.

Return vs Market: A042520 underperformed the KR Market which returned -16.3% over the past year.

Price Volatility

Is A042520's price volatile compared to industry and market?
A042520 volatility
A042520 Average Weekly Movement2.9%
Biotechs Industry Average Movement6.5%
Market Average Movement5.5%
10% most volatile stocks in KR Market10.4%
10% least volatile stocks in KR Market3.1%

Stable Share Price: A042520 is less volatile than 75% of KR stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: A042520's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1993270Guen Young Kimhttps://www.hansbiomed.com

HansBiomed Corporation, together with its subsidiaries, engages in the research and development, production, and sale of medical materials for the procedure and the raw materials for medical supplies. The company provides ExFuse, a demineralized bone matrix with cancellous bone gel/putty; BellaFuse, a demineralized bone matrix; Genesis, a cancellous sponge block/filler; Pedi-Stick, a demineralized cortical bone stick; SureChip, a cancellous bone chip; OsteoGrow, a demineralized bone matrix inserter; BellaCell HD, an allograft dermal product that transplanted in a patient whose skin has been lost due to breast cancer; and SureDerm, an acellular dermal matrix. It also offers BELLAGEL, a breast prosthesis, internal, and gel-filled solution; MINT Lift, a PDO thread; EZ-Tcon solution; Lion HT/HN, a hair transplanter body/needle; and Scar Clinic, a scar management solution.

HansBiomed Fundamentals Summary

How do HansBiomed's earnings and revenue compare to its market cap?
A042520 fundamental statistics
Market Cap₩103.52b
Earnings (TTM)-₩22.37b
Revenue (TTM)₩58.28b

1.8x

P/S Ratio

-4.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
A042520 income statement (TTM)
Revenue₩58.28b
Cost of Revenue₩28.85b
Gross Profit₩29.44b
Other Expenses₩51.81b
Earnings-₩22.37b

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-2.29k
Gross Margin50.51%
Net Profit Margin-38.39%
Debt/Equity Ratio128.2%

How did A042520 perform over the long term?

See historical performance and comparison

Valuation

Is HansBiomed undervalued compared to its fair value and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


2.42x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate A042520's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A042520's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: A042520 is unprofitable, so we can't compare its PE Ratio to the KR Biotechs industry average.

PE vs Market: A042520 is unprofitable, so we can't compare its PE Ratio to the KR market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate A042520's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: A042520 is good value based on its PB Ratio (2.4x) compared to the KR Biotechs industry average (3.3x).


Future Growth

How is HansBiomed forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


13.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as HansBiomed has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has HansBiomed performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-60.1%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: A042520 is currently unprofitable.

Growing Profit Margin: A042520 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: A042520 is unprofitable, and losses have increased over the past 5 years at a rate of 60.1% per year.

Accelerating Growth: Unable to compare A042520's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A042520 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (20.1%).


Return on Equity

High ROE: A042520 has a negative Return on Equity (-57.65%), as it is currently unprofitable.


Financial Health

How is HansBiomed's financial position?

Financial Health Score

1/6

Financial Health Score 1/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: A042520's short term assets (₩64.9B) do not cover its short term liabilities (₩67.5B).

Long Term Liabilities: A042520's short term assets (₩64.9B) exceed its long term liabilities (₩30.2B).


Debt to Equity History and Analysis

Debt Level: A042520's net debt to equity ratio (57%) is considered high.

Reducing Debt: A042520's debt to equity ratio has increased from 32.8% to 128.2% over the past 5 years.

Debt Coverage: A042520's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: Insufficient data to determine if A042520's interest payments on its debt are well covered by EBIT.


Balance Sheet


Dividend

What is HansBiomed current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate A042520's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate A042520's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if A042520's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if A042520's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: A042520 is not paying a notable dividend for the KR market.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as A042520 has not reported any payouts.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Guen Young Kim

1.33yrs

Tenure

Guen Young Kim serves as Chief Executive Officer of HansBiomed Corp. since January 2021.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

HansBiomed Corporation's employee growth, exchange listings and data sources


Key Information

  • Name: HansBiomed Corporation
  • Ticker: A042520
  • Exchange: KOSDAQ
  • Founded: 1993
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: ₩103.518b
  • Shares outstanding: 9.77m
  • Website: https://www.hansbiomed.com

Number of Employees


Location

  • HansBiomed Corporation
  • 7, Jeongui-ro 8-gil
  • Songpa-gu
  • Seoul
  • South Korea

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/11 00:00
End of Day Share Price2022/05/11 00:00
Earnings2021/12/31
Annual Earnings2021/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.